The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.
The allogeneic stem cell transplantation is the only curative treatment for myelofibrosis. However, because of complications such as infection, graft-versus-host disease and conditioning toxicity, this procedure is associated with a high morbidity-mortality rate. The discovery of molecular and genetic markers permitted to improve therapeutic strategy and survival of patient in the last few years. In this study, the investigators want to make an overview of survival, incidence of relapse and incidence of acute and chronic graft versus host disease in allogeneic stem cell transplantation for myelofibrosis, in five centers in France, between 2007 and 2017.
Study Type
OBSERVATIONAL
Enrollment
58
survival
incidence of survival in the cohort
Time frame: at 1 year
incidence of relapse
incidence of relapse in the cohort
Time frame: at 1 year
incidence of acute graft versus host disease
incidence of acute graft versus host disease in the cohort
Time frame: at 3 months
incidence of chronic graft versus host disease
incidence of chronic graft versus host disease in the cohort
Time frame: at 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.